Back to portfolio
The program focuses on developing peptide allosteric modulators of the urotensinergic system. Urotensin II is the most potent vasoconstrictor identified to date. This program is being led by Dr. David Chatenet from the Institut National de Recherche Scientifique – Institut Armand Frappier. Allosteric modulators have been tested in animal models of pulmonary arterial hypertension.